UNSPSC 51282407: Mezlocillin

This classification denotes an extended spectrum penicillin antibiotic with the molecular formula C21H25N5O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OH2O403D1G, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9ci) but generally known as mezlocillin, which bears US NIH Compound Identifier 3715. European Medicines Agency schedules Mezlocillin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08938MIG.

UNSPSC 51282407 Mezlocillin is a Commodity code for a specific pharmaceutical product, but recent state and local procurement activity under this code shows minimal direct relevance. The one opportunity explicitly tagged with the code—Seminole County, Florida's IFB 60459723LAS—actually solicits Naloxone and Safe Drug Deactivation Systems, not mezlocillin. The mismatch suggests either a cataloging error or a jurisdictional tagging practice that does not align the nominal code with the goods being procured. State and local governments do procure generic and branded pharmaceuticals through various mechanisms, as evidenced by concurrent activity in related therapeutic-category and OTC-product codes, but the mezlocillin code itself does not show material recent activity under its strict product definition.

Recent pharmaceutical procurement in Florida, Texas, Minnesota, and other jurisdictions is concentrated in multi-source generic contracting, cooperative purchasing agreements, and direct-to-manufacturer prescription programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, due March 26, 2026) establishes contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities; the Texas Health and Human Services Commission's RFI HHS0017013 (April 3, 2026) explores direct-to-manufacturer prescription models; and the City of Tampa's IFB 26P00145 (due March 13, 2026) procures medical and first aid supplies for the Fire Department. These opportunities reflect state and local demand for pharmaceuticals through wholesaler networks, cooperative vehicles, and emergency-response supply chains, but none directly references mezlocillin. Firms pursuing pharmaceutical opportunities in the state and local space should track cooperative purchasing RFPs and generic-drug family codes rather than wait for direct mezlocillin solicitations.